NRCT-101SR
ADHD
Key Facts
About Neurocentria
Neurocentria is a private, late-stage biotech pioneering a new class of therapies based on the novel mechanism of elevating intracellular magnesium at synapses to promote synaptogenesis and enhance synaptic function. Its lead drug candidate, NRCT-101SR, is in Phase 2b/3 trials for ADHD, depression, and Alzheimer's disease, with early clinical data showing rapid mood improvement and cognitive benefits. The company also has a revenue-generating nutraceutical arm, Magtein®, which serves as a commercial foundation and proof-of-concept for its core science.
View full company profileAbout Neurocentria
Neurocentria is a private, late-stage biotech pioneering a new class of therapies based on the novel mechanism of elevating intracellular magnesium at synapses to promote synaptogenesis and enhance synaptic function. Its lead drug candidate, NRCT-101SR, is in Phase 2b/3 trials for ADHD, depression, and Alzheimer's disease, with early clinical data showing rapid mood improvement and cognitive benefits. The company also has a revenue-generating nutraceutical arm, Magtein®, which serves as a commercial foundation and proof-of-concept for its core science.
View full company profileAbout Neurocentria
Neurocentria is a private, late-stage biotech pioneering a new class of therapies based on the novel mechanism of elevating intracellular magnesium at synapses to promote synaptogenesis and enhance synaptic function. Its lead drug candidate, NRCT-101SR, is in Phase 2b/3 trials for ADHD, depression, and Alzheimer's disease, with early clinical data showing rapid mood improvement and cognitive benefits. The company also has a revenue-generating nutraceutical arm, Magtein®, which serves as a commercial foundation and proof-of-concept for its core science.
View full company profileTherapeutic Areas
Other ADHD Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program | Curemark | Preclinical |
| XELSTRYM | Noven Pharmaceuticals | Approved |
| DAYTRANA | Noven Pharmaceuticals | Approved |
| QELBREE (viloxazine ER) | Supernus Pharmaceuticals | Approved |
| JORNAY PM | Collegium Pharmaceutical | Marketed |
| AZSTARYS | Collegium Pharmaceutical | Acquisition Pending |
| CTx-1301 | Cingulate | Phase 3 |
| CTx-1302 | Cingulate | Phase 3 |